ArticleEuropean journal of nuclear medicine and molecular imaging2016
[(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2016Trial
- Review
- Diagnostic Value of [Molecular imaging and biology · 2025Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.Molecules (Basel, Switzerland) · 2022Review
- Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer.Cancers · 2022Article
- Review
- Head-to-Head Comparison of NeckCancers · 2021Article
- Value ofCancer management and research · 2021Article
- [Indications and results of radioiodine treatment of differentiated thyroid cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020Review
- Comparison of simultaneousEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Incremental diagnostic value of [European journal of nuclear medicine and molecular imaging · 2020Article
- Hybrid PET/MRI in major cancers: a scoping review.European journal of nuclear medicine and molecular imaging · 2019Article
- Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.Medical oncology (Northwood, London, England) · 2017Review
- FDG Whole-Body PET/MRI in Oncology: a Systematic Review.Nuclear medicine and molecular imaging · 2017Review
- Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Article
- PET and MRI: Is the Whole Greater than the Sum of Its Parts?Cancer research · 2016Article
- Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany.Molecular imaging and biology · 2016Article
- Imaging of differentiated thyroid carcinoma: (124)I-PET/MRI may not be superior to (124)I-PET/CT.European journal of nuclear medicine and molecular imaging · 2016Article
- Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2016Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic potential of PET/MRI with [(18)F]FDG in comparison to PET/CT in patients with differentiated thyroid cancer suspected or known to have dedifferentiated.
methodsThe study included 31 thyroidectomized and remnant-ablated patients who underwent a scheduled [(18)F]FDG PET/CT scan and were then enrolled for a PET/MRI scan of the neck and thorax. The datasets (PET/CT, PET/MRI) were rated regarding lesion count, conspicuity, diameter and characterization. Standardized uptake values were determined for all [(18)F]FDG-positive lesions. Histology, cytology, and examinations before and after treatment served as the standards of reference.
resultsOf 26 patients with a dedifferentiated tumour burden, 25 were correctly identified by both [(18)F]FDG PET/CT and PET/MRI. Detection rates by PET/CT and PET/MRI were 97 % (113 of 116 lesions) and 85 % (99 of 113 lesions) for malignant lesions, and 100 % (48 of 48 lesions) and 77 % (37 of 48 lesions) for benign lesions, respectively. Lesion conspicuity was higher on PET/CT for both malignant and benign pulmonary lesions and in the overall rating for malignant lesions (p < 0.001). There was a difference between PET/CT and PET/MRI in overall evaluation of malignant lesions (p < 0.01) and detection of pulmonary metastases (p < 0.001). Surgical evaluation revealed three malignant lesions missed by both modalities. PET/MRI additionally failed to detect 14 pulmonary metastases and 11 benign lesions.
conclusionIn patients with thyroid cancer and suspected or known dedifferentiation, [(18)F]FDG PET/MRI was inferior to low-dose [(18)F]FDG PET/CT for the assessment of pulmonary status. However, for the assessment of cervical status, [(18)F]FDG PET/MRI was equal to contrast-enhanced neck [(18)F]FDG PET/CT. Therefore, [(18)F]FDG PET/MRI combined with a low-dose CT scan of the thorax may provide an imaging solution when high-quality imaging is needed and high-energy CT is undesirable or the use of a contrast agent is contraindicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.